WuXi Biologics (Cayman) Total Liabilities

WuXi Biologics (Cayman) (WXIBF) currently reports a total liabilities of $11B as of June 2026. That compares with $11B in the prior-year period — down 5.0% year over year. Use the charts on this page to explore WuXi Biologics (Cayman)'s total liabilities history and peer comparisons.

WuXi Biologics (Cayman)'s total liabilities decreased from $11B to $11B — a 5.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

WuXi Biologics (Cayman) reported $11B in total liabilities as of June 2026. That compares with $11B in the prior-year period — down 5.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $11B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for WuXi Biologics (Cayman), and consider following WXIBF for alerts when major investors trade the stock.

WuXi Biologics (Cayman) is classified in the Healthcare sector. On total liabilities, it currently shows $11B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing WXIBF with unrelated industries.